 |
|
|
|
|
|
 Title: |
US5700822:
Treatment of platelet derived growth factor related disorders such as cancers
[ Derwent Title ]
>> View Certificate of Correction for this publication
|
| Country: |
US United States of America
|
| |
| Inventor: |
Hirth, Klaus Peter; San Francisco, CA
Schwartz, Donna Pruess; San Mateo, CA
Mann, Elaina; Alameda, CA
Shawver, Laura Kay; San Francisco, CA
Keri, Gyorgi; Budapest, Hungary
Szekely, Istvan; Dunakeszi, Hungary
Bajor, Tamas; Budapest, Hungary
Haimichael, Janis; Budapest, Hungary
Orfi, Laszlo; Budapest, Hungary
Levitzki, Alex; Jerusalem, Israel
Gazit, Aviv; Jerusalem, Israel
Ullrich, Axel; Munich, Germany
Lammers, Reiner; Munich, Germany
Kabbinavar, Fairooz F.; Woodland Hills, CA
Slamon, Dennis; Woodland Hills, CA
Tang, Peng Cho; Moraga, CA
|
| Assignee: |
The Regents of the University of California, Oakland, CA
other patents from UNIVERSITY OF CALIFORNIA, THE REGENTS OF (599425) (approx. 4,840)
News, Profiles, Stocks and More about this company
|
| Published / Filed: |
1997-12-23
/ 1995-06-01
|
| Application Number: |
US1995000457047
|
| IPC Code: |
Advanced:
A61K 9/00;
A61K 31/165;
A61K 31/167;
A61K 31/275;
A61K 31/277;
A61K 31/38;
A61K 31/40;
A61K 31/415;
A61K 31/42;
A61K 31/421;
A61K 31/425;
A61K 31/44;
A61K 31/47;
A61K 31/495;
A61K 31/505;
A61K 31/535;
A61K 45/06;
A61K 47/10;
A61K 47/26;
C07C 255/23;
C07D 231/38;
C07D 239/91;
C07D 241/38;
C07D 241/42;
C07D 487/04;
C07D 498/04;
G01N 33/50;
Core:
A61K 45/00;
C07C 255/00;
C07D 231/00;
C07D 239/00;
C07D 241/00;
C07D 487/00;
C07D 498/00;
more...
IPC-7:
A61K 31/42;
|
| ECLA Code: |
C07D231/38; A61K9/00M5; A61K31/165; A61K31/167; A61K31/275; A61K31/277; A61K31/38; A61K31/40; A61K31/415; A61K31/42; A61K31/42+A; A61K31/421; A61K31/425; A61K31/44; A61K31/47; A61K31/495; A61K31/505; A61K31/535; A61K45/06; A61K45/06+M; A61K47/10; A61K47/26; C07C255/23; C07D239/91; C07D241/38; C07D241/42; C07D487/04; G01N33/50D2B; M07D487/04+239C+235C; M07D498/04+265C+239C; M07D231/38B3D; M07D239/91; M07D241/38B; M07D241/42; M07D487/04; M07D498/04;
|
| U.S. Class: |
Current:
514/380;
514/379;
Original:
514/380;
514/379;
|
| Field of Search: |
514/379,380
|
| Priority Number: |
|
| Abstract: |
The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.
|
| Attorney, Agent or Firm: |
Lyon & Lyon LLP ;
|
| Primary / Asst. Examiners: |
Criares, Theodore J.;
|
| Maintenance Status: |
E2 Expired Check current status
CC Certificate of Correction issued
View Certificate of Correction
|
| INPADOC Legal Status: |
Show legal status actions
Family Legal Status Report
|
|
|
|
|
|
|
| Related Applications: |
| Application Number |
Filed |
Patent |
Pub. Date |
Title |
|---|
| US1995000370574 | 1995-01-06 |
|
|
|
| US1994000179570 | 1994-01-07 |
|
|
|
|
|
|
|
|
|
|
| Parent Case: |
RELATED APPLICATION
The present application is a continuation of application 08/370,574, filed Jan. 6, 1995 which is a continuation-in-part of Hirth et al., entitled "TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCERS" U.S. Ser. No. 08/179,570, filed Jan. 7, 1994, the entire contents of which including the drawings are hereby incorporated by reference herein.
|
| Designated Country: |
AM AP BB BG BR BY CZ EE FI GE HU JP KE KG KP KR KZ LK LR LT LV BE CH FR GB IE IT LI LU MC
|
| Family: |
Show 57 known family members
|
First Claim:
Show all 24 claims |
We claim:
1. A method of treating a patient suffering from a solid tumor characterized by inappropriate PDGF-R activity, comprising the step of administering to said patient a therapeutically effective amount of a compound selected from the group consisting of:
- a) a Group 1 compound having the chemical structure: [Figure] wherein R1, R2, R'2, R"2, and R'"2 are independently selected from the group consisting of hydrogen, halogen, trihalomethyl, and NO2 ; and R3 is selected from the group consisting of hydrogen, carboxy, and carbalkoxy, and
- b) a Group 2 compound having the chemical structure [Figure] wherein R4 and R5 are each independently halogen, hydrogen, trihalomethyl, or NO2 ; and R6 is either aryl, alkyl, alkenyl, or alkynyl; or a pharmaceutically acceptable salt of said compound;
- wherein said compound inhibits one or more PDGF-R activities in vivo or in vitro;
- wherein said patient is a human and said solid tumor is a cancer selected from the group consisting of intra-axial brain cancer, ovarian cancer, colon cancer, prostate cancer, lung cancer, Kaposi's sarcoma, and melanoma.
|
| Background / Summary: |
Show background / summary
|
| Drawing Descriptions: |
Show drawing descriptions
|
| Description: |
Show description
|
| Forward References: |
Show 16 U.S. patent(s) that reference this one
|
|
|
|
|
|
|
| Foreign References: |
Buy
PDF |
Publication |
Date |
IPC Code |
Assignee |
Title |
| |
AU3101093
|
1993-01 |
|
|
|
 |
EP0413329
|
1991-02 |
A61K 31/165
|
ALCON LAB INC
|
5-Methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic acid anilides for the treatment of ocular diseases |
|
EP0520722
|
1992-06 |
A61K 31/505
|
ICI PLC
|
Therapeutic preparations containing quinazoline derivatives |
|
EP0537742
|
1993-04 |
C07C 45/00
|
MITSUBISHI KASEI CORPORATION
|
Styrene derivatives |
|
EP0551230
|
1993-07 |
A61K 31/165
|
ROUSSEL UCLAF
|
Cyano-2-hydroxy-3-enamide derivatives, process for their preparation, their use as drugs, pharmaceutical compositions containing them and intermediates obtained |
|
EP0607777
|
1994-07 |
A61K 31/275
|
HOECHST AG
|
Use of leflunomid for the inhibition of interleukin 8 |
|
EP0607775
|
1994-07 |
A61K 31/275
|
HOECHST AG
|
Use of leflunomid for the inhibition of interleukin 1 beta |
|
EP0607776
|
1994-07 |
A61K 31/42
|
HOECHST AG
|
Use of leflunomid for the inhibition of tumor necrosis factor alpha |
|
EP0665013
|
1995-08 |
A61K 31/275
|
HOECHST AKTIENGESELLSCHAFT
|
Method of treating hyperproliferative vascular disease |
 |
DE2524929
|
1976-12 |
A61K 31/275
|
Hoechst AG, 6000 Frankfurt
|
Neue Cyanessigsaeureanilid-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Mittel |
|
GB2240104
|
1991-07 |
A61K 31/165
|
ERBA CARLO SPA
|
Arylvinylamide derivatives |
|
WO8704436
|
1987-07 |
C07D 487/00
|
AKERFELDT, Stig, Gustaf
|
SUBSTITUTED INDOLOQUINOXALINES |
|
WO9117748
|
1991-11 |
A61K 31/275
|
BARTLETT, Robert, R.
|
ISOXAZOLE-4-CARBOXAMIDES AND HYDROXYALKYLIDENE-CYANOACETAMIDES, DRUGS CONTAINING THESE COMPOUNDS AND USE OF SUCH DRUGS |
|
WO9221641
|
1992-04 |
A61K 31/12
|
DOW, Robert, L.
|
DIHYDROXYINDANONE TYROSINE KINASE INHIBITORS |
|
WO9218481
|
1992-10 |
A61K 31/44
|
GAZIT, Aviv
|
STYRYL-SUBSTITUTED HETEROARYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR TYROSINE KINASE |
|
WO9220642
|
1992-11 |
A61K 31/075
|
MAGUIRE, Martin, P.
|
BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE |
|
WO9426260
|
1994-11 |
A61K 31/165
|
BEN-NERIAH, Yinon
|
METHODS AND COMPOUNDS FOR INHIBITING CELL PROLIFERATIVE DISORDERS CHARACTERIZED BY ABNORMAL abl ACTIVITY |
|
WO9521613
|
1995-08 |
A61K 31/24
|
SUGEN INC
|
COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS |
|
| Other Abstract Info: |
CHEMABS 124(03)021813M
CHEMABS 126(20)268519P
CHEMABS 131(26)346563T
DERABS C1995-263705
|
| Other References: |
Andrews et al. (American Veterinary Medicine Association Panel on Euthanasia), "1993 Report of the AVMA Panel on Authanasia," J. American Veterinary Medicine Association 202(2):229-249 (1993).
Bartlett et al., "Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection," Agents and Actions 32:10-21 (1991).
(12 pages)
Cited by 31 patents
[ISI abstract]
Bartlett et al., "Effects of leflunomide on immune responses and models of inflammation," Springer Semin. Immunopathol. 14:381-394 (1993).
(14 pages)
Cited by 15 patents
[ISI abstract]
Bartlett et al., "Leflunomide: A novel immunomodulating drug" in Nonsteroidal Anti-Inflammatory Drugs 2nd ed. pp. 349-366, Lewis and Furstk eds., Dekker, NY NY (1989).
Baselga et al., "Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal Antibodies," J. of Natl. Cancer Institute 85(16): 1327-1333 (1993).
(7 pages)
Cited by 18 patents
[ISI abstract]
Baudy et al., "Potent Quinoxaline-Spaced Phosphono α-Amino Acids of the AP-6 Type as Competitive NMDA Antagonists: Synthesis and Biological Evaluation," J. Med. Chem. 36:331-342 (1993).
(12 pages)
Cited by 15 patents
[ISI abstract]
Bilder et al., "Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells," Am. J. Physiol. 260(Cell Physiol.29):C721-C730 (1991).
(10 pages)
Cited by 32 patents
[ISI abstract]
Birchall et al., "Compositions for killing internal parasites containing 3-teri-alkyl-4-hydroxy-5-halobenzylidene-malononitriles," Chemical Abstracts 88:535 (1978).
Bristol Laboratories Oncology Products, "VePesid (Etoposide) For Injection and Capsules," Dec. 1992.
Bryckaert et al., "Inhibition of Platelet-Derived Growth Factor-Induced Mitogenesis and Tyrosine Kinase Activity in Cultured Bone Marrow Fibroblasts by Tyrphostins," Exp. Cell Research 199:255-261 (1992).
(7 pages)
Cited by 30 patents
[ISI abstract]
Bustelo and Barbacid, "Tyrosine Phosphorylation of the vav Proto-lncogene Product in Activated B Cells," Science 256:1196-1199 (1992).
(4 pages)
Cited by 13 patents
[ISI abstract]
Caraglia et al., "Cytosine arabinoside increases the binding of 125 I-labelled epidermal grow factor and 125 l-transferrin and enhances the in vitro targeting of human tumour cells with anti-(growth factor receptor)mAb," Cancer Immunol. Immunother. 37:150-156 (1993).
(7 pages)
Cited by 16 patents
[ISI abstract]
Carboni et al., "Cyanocarbon Chemistry. XI. Malononitrile Dimer," J. Am. Chem. Soc. 80:2838-2840 (1958).
Cecil Textbook of Medicine, eds. Wyngaarden, Smith, Bennett, W.B. Saunders (1992) p. 2220.
Chen and Okayama, "Calcium Phosphate-Mediated Gene Transfer: A Highly Efficient Transfection System for Stably Transforming Cells with Plasmid DNA," BioTech. 6:632-638 (1988).
Cited by 42 patents
Cherwinski et al., "The Immunosuppressant Leflunomide Inhibits Lymphocyte Progression Through Cell Cycle by a Novel Mechanism," J. Pharmacology and Exp. Therap. 272:460-468 (1995).
(9 pages)
Cited by 15 patents
[ISI abstract]
Chong et al., "Leflunomide, a Novel Immunosuppressive Agent," Transplantation 55:1361-1366 (1993).
(6 pages)
Cited by 17 patents
[ISI abstract]
Chong et al., "Leflunomide, a Novel Immunomodulatory Agent: In Vitro Analyses of the Mechanism of Immunosupression," Transplant. Proc. 25:747-749 (1993).
(3 pages)
Cited by 17 patents
[ISI abstract]
Conn et al., "Purification of a glycoprotein vascular endothelial cell mitogen from a rat glimo-derived cell line," Proc. Natl. Acad. Sci. USA 87:1323-1327 (1990).
(5 pages)
Cited by 32 patents
Dati et al., "Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells," Oncogene 5:1001-1006 (1990).
(6 pages)
Cited by 38 patents
Decker and Lohmann-Matthes, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," J. Immunol. Methods 115:61-69 (1988).
(9 pages)
Cited by 68 patents
Ehrlich and Bogert, "Experiments in the Veratrole and Quinoxaline Groups," J. Org. Chem. 12:522 (1947).
Ferris et al., "Synthesis of Zuinazoline Nucleosides from Ribose and Anthranilonitrile. Application of Phase-Transfer Catalysis in Nucleoside Synthesis," J. Org. Chem. 44(2):173-178 (l (1979).
(6 pages)
Cited by 33 patents
Floege et al., "Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo," Kidney International 435:47-54 (1993).
Fry et al., "New insights into protein-tyrosine kinase receptor signaling complexes," Protein Science 2:1785-1797 (1993).
(13 pages)
Cited by 38 patents
[ISI abstract]
Gazit et al., "Tyrphostins. 1. Synthesis and Biological Activity of Protein Tyrosine Kinase Inhibitors," J. Med. Chem. 32:2344-2352 (1989).
(9 pages)
Cited by 47 patents
Gazit et al., "Tyrphostins. 2. Heterocyclic and α-Substituted Benzylidenemalononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases," J. Med. Chem. 34:1896-1907 (1991).
(12 pages)
Cited by 59 patents
[ISI abstract]
Gazit et al., "Tyrphostins. 3. Structure-Activity Relationship Studies of a α-Substituted Benzylidenemalononitrile 5-S-Aryltyrphostins" J. Med. Chem. 36:3556-3564 (1993).
(9 pages)
Cited by 38 patents
[ISI abstract]
Glant et al., "lmmunodulation of proteoglycan-induced progressive polyarthritis by leflunomide." Immunopharmacology 23:105-116 (1992).
(12 pages)
Cited by 20 patents
[ISI abstract]
Gottardis et al., "Estradiol-Stimulated Growth of MCF-7 Tumors Implanted in Athymic Mice: A Model to Study the Tumoristatic Action of Tamoxifen," J. Steroid Biochem. 30(1-6):331-314 (1988).
Gulbins et al., "Tyrosine Kinase-Stimulated Guanine Nucleotide Exchange Activity of Vav in T Cell Activation," Science 260:822-825 (1993).
(4 pages)
Cited by 10 patents
[ISI abstract]
Hale et al., "Prognostic value of epidermal growth factor receptor expression in cervical carcinoma," J. Clin. Pathol. 46:149-153 (1993).
(5 pages)
Cited by 18 patents
[ISI abstract]
Harris et al., "Breast Cancer (First of Three Parts)," New England J. of Medicine 327(5):319-328 (1992).
(10 pages)
Cited by 33 patents
[ISI abstract]
Heldin, "Structural and functional studies on platelet-derived growth factor," EMBO Journal 11:4251-4259 (1992).
(9 pages)
Cited by 14 patents
[ISI abstract]
Hoekstra et al., "Differential effects of steurosporine and tyrphostins on receptor tyrosine kinase autophosphorylation and peptide substrate phosphorylation," Experimental Therapeutics from 84th Annual Meeting of American Association for Cancer Research, Vol. 34, #2455 (1993).
Honegger et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," Cell 5:199-209 (1987).
(11 pages)
Cited by 61 patents
Houck et al., "The Vascular Endothelial Growth Factor Family: Identification of a Fourth Molecular Species and Characterization of Alternative Splicing of RNA," Molecular Endocrinology 5:1806-1814 (1991).
(9 pages)
Cited by 41 patents
[ISI abstract]
Issidorides and Haddadin, "Benzofurazan Oxide. II. Reactions with Enolate Anions," J. Org. Chem. 31:4067-4068 (1966).
Ju et al., "Leflunomide inhibits cytokine-induced DNA synthesis of rabbit synovial cells in culture," Acta Pharmacological Sinica 15:223-226 (1994).
(4 pages)
Cited by 11 patents
[ISI abstract]
Ju et al., "Leflunomide inhibits PAF induced DNA synthesis in rabbit synovial cells and PAF production from rat peritomeal macrophages," Acta Pharmacological Sinica 92:90-94 (1994).
Karameris et al., "Expression of Epidermal Growth Factor (EGF) and Epidermal Growth Factor Receptor (EGFR) in Gastric and Colorectal Carcinomas, An Immunohistological Study of 63 Cases," Path. Res. Pract. 189:133-137 (1993).
(5 pages)
Cited by 15 patents
[ISI abstract]
Kaur, "Tyrphostin induced growth inhibition: correlation with effect on p210ber-abl autokinase activity in K562 chronic myelogenous leukemia," Anti-Cancer Drugs 5:213-222 (1994).
(10 pages)
Cited by 30 patents
[ISI abstract]
Koenders et al., "Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study," Breast Cancer Research and Treatment 25:21-27 (1993).
(7 pages)
Cited by 16 patents
[ISI abstract]
Korzeniewski and Callewaert, "An Enzyme-Release Assay for Natural Cytotoxicity1," J. Immunol. Methods 64:313 (1983).
(8 pages)
Cited by 58 patents
Kovalenko et al., "Selective Platelet-derived Growth Factor Receptor Kinase Blockers Reverse sis-Transformation," Transformation, Cancer Research 54:6106-6114 (1994).
(9 pages)
Cited by 20 patents
[ISI abstract]
Kuchle et al., "Prevention of Kidney and Skin Graft Rejection in Rats by Leflunomide, a New Immunomodulating Agent," Transplantation Proceedings 23:1083-1086 (1991).
(4 pages)
Cited by 9 patents
[ISI abstract]
Lee and Salemnick, "Purine N-Oxides, LXII. 2,4-Dioxopyrido[2,3-d]pyrimidine N-Oxides," J. Org. Chem. 40(24):3608-3610 (1975).
(3 pages)
Cited by 14 patents
Levitzki, "Tyrphostins--Potential Antiproliferative Agents and Novel Molecular Tools," Biochem. Pharm. 40(5):913-918 (1990).
(6 pages)
Cited by 18 patents
Ley and Seng, "Synthesen unter Verwendung von Benzofuroxan," Synthesis 1975:415-422 (1975).
(8 pages)
Cited by 33 patents
Lyall et al., "Tyrphostins Inhibit Epidermal Growth Factor (EGF)-Receptor Tyrosine Kinase Activity in Living Cells and EGF-stimulated Cell Proliferation," J. Bio. Chem., 264: 14503-14509 (1989).
(7 pages)
Cited by 37 patents
Marshall, E., "Search for a Killer: Focus Shifts from Fat to Hormones," Science 259:618-621 (1993).
Cited by 24 patents
[ISI abstract]
Mattar et al., "Effects of leflunomides active metabolite, A771726, on signal transduction pathways necessary for proliferation," Immunobiology 186(1-2):43 (1992) (abstract).
Mattar et al., "Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide," FEBS Letters Vol. 334:161-164 (1993).
(4 pages)
Cited by 27 patents
[ISI abstract]
McChesney et al., "An Evaluation of Leflunomide in the Canine Renal Transplantation Model," Transplantation 57:1717-1722 (1994).
(6 pages)
Cited by 15 patents
[ISI abstract]
Millauer et al., "High Affinity VEGF Binding and Developmental Expression Suggest FIk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," Cell 7.2:835-846 (1993).
(12 pages)
Cited by 103 patents
[ISI abstract]
Mosmann, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," J. Immunol. Methods 65:55-63 (1983).
(9 pages)
Cited by 214 patents
Muller et al., "BCR First Exon Sequences Specifically Activate the BCR/ABL Tyrosine Kinase Oncogene of Philadelphia Chromosome-Positive Human Leukemias," Mol. Cell. Biol. 11:1785-1792 (1991).
(8 pages)
Cited by 31 patents
[ISI abstract]
Nichterlein et al., "Leflunomide (HWA 486) Prolongs Course of Murine Listeriosis," Immunol. Infect. Dis. 4:18-22 (1994).
Ogawa et al., "Therapeutic Effects of Leflunomide, a New Antirheumatic Drug, on Glomerulonephritis Induced by the Antibasement Membrane Antibody in Rats," Clin. Immunol. Immunopath. 61:103-118 (1991).
(16 pages)
Cited by 17 patents
[ISI abstract]
Ogawa et al., "Effects of leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats," Agents Actions 31:321-328 (1990).
(8 pages)
Cited by 17 patents
Ohmichi et al., "The Tyrosine Kinase Inhibitor Tyrphostin Blocks the Cellular Actions of Nerve Growth Factor," Biochemistry 32:4650-4658 (1993).
(9 pages)
Cited by 24 patents
[ISI abstract]
Osborne et al., "Effect of Estrogens and Antiestrogens on Growth of Human Breast Cancer Cells in Athymic Nude Mice," Cancer Research 45:584-590 (1985).
(7 pages)
Cited by 45 patents
Osherov et al., "Selective Inhibition of the EGF and Neu receptors by Tyrophostins," J. Cell Biochem. 517A:237 (1993).
Osherov et al., "Selective Inhibition of the Epidermal Growth Factor and HER2/Neu Receptors by Tyrphostins," J. Bio. Chem. 268:11134-11142 (1993).
(9 pages)
Cited by 18 patents
[ISI abstract]
Ozzello and Sordat, "Behavior of Tumors Produced by Transplantation of Human Mammary Cell Lines in Athymic Nude Mice," Eur. J. Cancer 16:553-559 (1980).
(7 pages)
Cited by 43 patents
Patterson et al., "3-Carboxy-5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide, a New Prodrug for the Antiarthritic Agent 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide," J. Med. Chem. 35:507-510 (1992).
(4 pages)
Cited by 9 patents
[ISI abstract]
Peterson and Barnes, "Genistein and Biochanin A Inhibit the Growth of Human Prostate Cancer Cells but not Epidermal Growth Factor Receptor Tyrosine Autophosphorylation," The Prostate 22:335-345 (1993).
(11 pages)
Cited by 49 patents
[ISI abstract]
Pigott et al., "Expression of epidermal growth factor receptor in human glioblastoma multiforme," Brit. J. of Neurosurgery 7:261-265 (1993).
(5 pages)
Cited by 14 patents
[ISI abstract]
Plate et al., "Vascular endothelial growth factor is a potential tumour angiogenesis factor in human glimoas in vivo," Nature 359:845-848 (1992).
(4 pages)
Cited by 81 patents
[ISI abstract]
Plate et al., "Up-Regulation of Vascular Endotheial Growth Factor and Its Cognate Receptors in a Rat Glimoa Model of Tumor Angiogenesis," Cancer Research 53:5822-5827 (1993).
(6 pages)
Cited by 49 patents
[ISI abstract]
Plate et al., "Platelet-Derived Growth Factor Receptor-β is Induced during Tumor Development and Upregulated during Tumor Progression in Endothelial Cells in Human Gliomas," Laboratory Investigation 4:529-534 (1992).
(6 pages)
Cited by 13 patents
[ISI abstract]
Pollack et al., "Response of malignant glioma cell lines to epidermal growth factor and platelet-derived growth factor in a serum-free medium," J. Neurosurg. 73:106-112 (1990).
(7 pages)
Cited by 12 patents
Ren et al., "Identification of a Ten-Amino Acid Proline-Rich 5H3 Binding Site," Science 259:1157-1161 (1993).
(5 pages)
Cited by 55 patents
[ISI abstract]
Rendu et al., "Inhibition of Platelet Activation by Tyrosine Kinase Inhibitors," Biochem. Pharm. 44(5):881-888 (1992).
(8 pages)
Cited by 33 patents
[ISI abstract]
Rosenthal et al., "Conditioned Medium from Mouse Sarcoma 180 Cells Contains Vascular Endothelial Growth Factor," Growth Factors 4:53-59 (1990).
Ross, "The pathogenesis of atherosclerosis: a perspective for the 1990s," Nature 362:801-809 (1993).
(9 pages)
Cited by 121 patents
[ISI abstract]
Rusch et al., "Differential Expression of the Epidermal Growth Factor Receptor and Its Lgands in Primary Non-Small Cell Lung Cancers and Adjacent Benign Lung," Cancer Research 53:2379-2385 (1993).
(7 pages)
Cited by 16 patents
[ISI abstract]
Rygaard and Povlsen, "Heterotransplantation of a Human Malignant Tumour to `Nude` Mice," Acta path. microbiol. scand. 77:758-760 (1969).
Schorlemmer et al., "Prolongation of Allogeneic Transplanted Skin Grafts and Induction of Tolerance by Leflunomide, a New Immunosuppresive Isoxazol Derivative," Transplant. Proc. 25:763-767 (1993).
(5 pages)
Cited by 18 patents
[ISI abstract]
Schornagel et al., "Synthesis and Evaluation of 2,4-Diaminoquinazoline Antifolates with Activity Against Methotrexate-Resistant Human Tumor Cells," Blochem. Pharm. 33 (20):3251-3255 (1984).
(5 pages)
Cited by 18 patents
Scott et al., "p185HER2 Signal Transduction in Breast Cancer Cells," J. Bio. Chem. 266(22):14300-14305 (1991).
(6 pages)
Cited by 30 patents
[ISI abstract]
Seibert et al., "Clonal Variation of MCF-7 Breast Cancer Cells in Vitro and in Athymic Nude Mice," Cancer Research 43:2223-2239 (1983).
(17 pages)
Cited by 40 patents
Shafie and Grantham, "Role of Hormones in Growth and Regression of Human Breast Cancer Cells (MCF-7) Transplanted into Athymic Nude Mice," J. Natl Cancer Institute 67(1):51-56 (1981).
(6 pages)
Cited by 41 patents
Shweiki et al., "Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis," Nature 359:843-845 (1992).
(3 pages)
Cited by 60 patents
[ISI abstract]
Skehan et al., "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening," J. Natl. Cancer Inst. 82:1107-1112 (1990).
(6 pages)
Cited by 107 patents
Talmadge and Twardzik, "Role of Cytokines in Inflammation and Autoimmunity," Agents and Actions 35S:135-141 (1991).
Thoenes et al., "Leflunomide (HWA 486) Inhibits Experimental Autoimmune Tubulointerstitial Nephritis in Rats," Int. J. Immunopharmacol. 11:921-929 (1989).
(9 pages)
Cited by 17 patents
Ueno et al., "Inhibition of PDGF β Receptor Signal Transduction by Coexpression of a Truncated Receptor," Science 252:844-252 (1991).
(5 pages)
Cited by 19 patents
[ISI abstract]
Ulrichs et al., "Suppression of Natural Xenophile Antibodies With the Novel Immunomodulating Drug Leflunomide," Transplant Proc. 24:718-719 (1992).
(2 pages)
Cited by 18 patents
[ISI abstract]
Wada et al., "Anti-receptor antibodies reverse the phenotype of cells transformed by two interacting proto-oncogene encoded receptor proteins," Oncogene 5:489-495 (1990).
(7 pages)
Cited by 27 patents
Waltenberger et al., "Different Signal Transduction Properties of KDR and Flt1, Two Receptors for Vascular Endothelial Growth Factor," J. Biol. Chem. 269:26988-26995 (1994).
(8 pages)
Cited by 43 patents
[ISI abstract]
Warri et al., "Estrogen Suppression of erbB2 Expression is Associated with Increased Growth Rate of ZR-75-1 Human Breast Cancer Cells In Vitro and in Nude Mice," Int. J. Cancer 49:616-623 (1991).
(8 pages)
Cited by 42 patents
[ISI abstract]
Weithmann et al., "Effect of leflunomide on constitutive and inducible pathways of cellular eicosanoid generation," Agents Actions 41:164-170 (1994).
(7 pages)
Cited by 15 patents
[ISI abstract]
Williams et al., "Immunosuppressive Effects of Leflunomide in a Cardiac Allograft Model," Transplantation Proc. 25:745-746 (1993).
(2 pages)
Cited by 19 patents
[ISI abstract]
Williams et al., "Leflunomide in Experimental Transplantation," Transplantation 57:1223-1231 (1994).
(9 pages)
Cited by 17 patents
[ISI abstract]
Xiao et al., "Effect of Leflunomide in Control of Acute Rejection in Hamster-to-Rat Cardiac Xenografts," Transplantation Proceedings 26:1263-1265 1994).
(3 pages)
Cited by 17 patents
[ISI abstract]
Xiao et al., "Leflunomide Controls Rejection in Hamster to Rat Cardiac Xenografts," Transplantation 58:828-834 (1994).
(7 pages)
Cited by 16 patents
[ISI abstract]
Yaish et al., "Blocking of EGF-Dependent Cell Proliferation by EGF Receptor Kinase Inhibitors," Science 242:933-935 (1988).
(3 pages)
Cited by 22 patents
Yoneda et al., "The Antiproliferative Effects of Tyroslne Kinase Inhibitors Tyrphostins on a Human Squamous Cell Carcinoma in Vitro and in Nude Mice," Cancer Research 51:4430-4435 (1991).
(6 pages)
Cited by 82 patents
[ISI abstract]
Zeillinger et al., "EGF-R and Steroid Receptors in Breast Cancer: A Comparison with Tumor Grading, Tumor Size, Lymph Node Involvement, and Agen," Clin. Biochem. 26:221-227 (1993)Andrews et al. (American Veterinary Medicine Association Panel on Euthanasia), 1993 Report of the AVMA Panel on Euthanasia, J. American Veterinary Medicine Association 202(2):229-249 (1993).
(7 pages)
Cited by 16 patents
[ISI abstract]
Zielinski et al., "Effects of leflunomide (HWA 486) on expression of lymphocyte activation markers," Agents Actions 38:(Special Conference Issue) C80-C82 (1993).
(3 pages)
Cited by 17 patents
[ISI abstract]
|
|
 Nominate this for the Gallery...
|
|
